Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis ... Investor's Business Daily HCV infection is the most common cause of liver transplantation in the United States and Europe. Recurrence of HCV infection is universal among patients with active disease at the time of transplantation and up to 50 percent develop cirrhosis of the ... Gilead Sciences, Inc. : Gilead Announces Phase 2 Results for Sofosbuvir-Based ... |
